Fairmount

Co-founded in 2016 by managing members Tomas Kiselak and Peter Harwin, Fairmount Funds Management is a registered investment adviser and healthcare-focused hedge fund headquartered in West Conshohocken, Pennsylvania. The firm executes strategic equity investments across public and private biotechnology markets, targeting emerging life sciences organizations that develop differentiated therapeutics with strong research pipelines and experienced management teams. Operating with a dedicated staff of 21 to 50 employees, the hedge fund earns management fees and performance incentives while overseeing more than $2,500,000,000 in assets under management. Generating approximately $2,900,000 in annual revenue, the investment manager maintains a highly concentrated strategy with a public equities portfolio valued at $1,300,000,000 across 13 core holdings. Notable recent portfolio activity includes an exit via the Zenas BioPharma IPO, alongside significant equity positions in biopharmaceutical developers Damora Therapeutics and Cogent Biosciences.